Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > My dream is

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Nov 13, 2021 10:16am

135 Views

Post# 34123002

RE:RE:RE:RE:RE:My dream is

I am not saying an analyst will not pick up coverage of TH, but I am saying that it is unlikely. I hope you are right and you should be right based on the facts surrounding TH's cancer prospects. They are intriguing enough to justify an analyst trying to get ahead of the pack on it. But the realist part of me just reminds me this is rare these days.

palinc2000 wrote:

Bank of America recently initiated coverage on AKRO ....joining 6 other firms covering Akro including Jefferies ,JP Morgan etc
Dont think there is a short term deal im sight
https://www.streetinsider.com/Analyst+Comments/BofA+Securities+Starts+Akero+Therapeutics+%28AKRO%29+at+Buy+%28Earlier%29/18926444.html?classic=1

Wino115 wrote: Completely agree, but as SPCEO often points out, the Wall St model is now based around deal compensation potential as opposed to commision generation via research. But who knows? Maybe an astute analyst will pick it up.

What I've found from trolling around on a lot of websites and reading some reports and industry views is that, like PL keeps saying, sortilin and it's function is a very new target and they are the first focusing on it. The Univ Gothemberg folks are #2 and they're trying a different angle, using a CATA (?) chemo to try to reduce the amount of sortilin, thus cancer stem cell propagation. So one issue is that both the PDC arena and the sortilin-as-cancer-target area are both really new so no analysts are really focused at all. They love CAR-T, immunotherapy, ADCs, TIGIT and various stem cell approaches. That's all the rage with analyst coverage. We'll get there, but it will take the science and data to perk up their attention. By then, hopefully we've made 2-3x and they will bring it the next 2-3x!

palinc2000 wrote: A credible cancer analyst could write without much hesitation that the upside potential is very high with a very limited downside risk if any......The only pre requisite before initiating coverage would be some belief in the chance of positive outcome based on the science,....

palinc2000 wrote: with a Speculative buy rating

palinc2000 wrote: That an oncology analyst intiates coverage on THTX soon before Phase 1 results